<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629692</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_15_03 V 12 Amendment 12</org_study_id>
    <nct_id>NCT02629692</nct_id>
  </id_info>
  <brief_title>Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies</brief_title>
  <official_title>A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic&#xD;
      activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A ( for Healthy volunteers) of the study is completed&#xD;
&#xD;
      Part B dose-escalation study is completed. Recruitment in dose-expansion is ongoing in India&#xD;
      and Korea&#xD;
&#xD;
      Part C study in subjects with treatment-refractory/intolerant is enrolling globally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Part A: Single ascending dose in healthy volunteers.&#xD;
Part B: Multiple ascending dose safety and tolerability study in subjects with CML or Ph + ALL.&#xD;
Part C: Efficacy and safety study in subjects with treatment refractory CML</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part B and C: Single arm (Open-label)&#xD;
Part A: 2 arms: Investigational agent arm and Placebo arm (Double-blind).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the Maximum Tolerated Dose (MTD) as determined by frequency of Dose Limiting Toxicities</measure>
    <time_frame>Dose Limiting toxicities observed over a 4 week period</time_frame>
    <description>PART B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent AEs as assessed by CTCAE v4.03</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For CML subjects in CP at study entry</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C: Proportion of subjects achieving Major Cytogenetic Response [ defined as complete cytogenetic response (CCyR; 0% Ph+metaphases) or partial cytogenetic response (PCyR; 1-35% Ph+ metaphases)] as assessed by conventional Karyotyping of Bone marrow aspirate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For CML subjects in AP at study entry</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C: Proportion of subjects achieving Major Hematologic Response [ defined as complete hematologic response (CHR) or no evidence of leukemia (NEL)] as assessed by complete blood count of peripheral blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For CML subjects in BP at study entry</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C: Proportion of subjects achieving Major Hematologic Response [defined as complete hematologic response (CHR) or no evidence of leukemia (NEL)] as assessed by complete blood count of peripheral blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of K0706 - Cmax [The maximum (peak) observed drug concentration after dose administration]</measure>
    <time_frame>All subjects will be followed for up to approximately 60 months after the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART B and PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Vodobatinib (K0706) - Tmax [The time to reach maximum (peak) drug concentration after dose administration]</measure>
    <time_frame>All subjects will be followed for up to approximately 60 months after the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART B and PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Vodobatinib (K0706) - Cmin [ Minimum observed drug concentration after dose administration]</measure>
    <time_frame>All subjects will be followed for up to approximately 60 months after the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART B and PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with CML- CP:Proportion of subjects achieving Complete Hematological Response as assessed by complete blood count of peripheral blood sample</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with CML- CP:Proportion of subjects achieving Complete Cytogenetic Response as assessed by conventional Karyotyping of Bone marrow aspirate</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with CML- CP:Proportion of subjects achieving Major Molecular Response as assessed by BCR-ABL transcript levels (BCR-ABL1 ratio of ≤ 0.1%) in peripheral blood using PCR (Polymerase Chain Reaction)</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with CML-AP &amp; BP: Proportion of subjects achieving Complete cytogenetic response as assessed by conventional Karyotyping of Bone marrow aspirate</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with CML-AP &amp; BP: Proportion of subjects achieving Partial Cytogenetic Response (PCyR) as assessed by conventional Karyotyping of Bone marrow aspirate</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of K0706</time_frame>
    <description>Part C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with CML-AP &amp; BP: Proportion of subjects achieving Major Molecular Response as assessed by BCR-ABL transcript levels (BCR-ABL1 ratio of ≤ 0.1%) in peripheral blood using PCR (Polymerase Chain Reaction)</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Major Cytogenetic Response (MCyR): Time to MCyR is the time from first dose to first MCyR (0-35% Ph+ metaphases) ; computed only for subjects who achieved MCyR</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Major Molecular Response : Time to MMR is the time from first dose to first MMR (BCR-ABL1 ratio of ≤ 0.1%) computed only for subjects who achieved MMR</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In all subjects Progression free survival (PFS)</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In all subjects Overall survival (OS)</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment emergent AEs as assessed by CTCAE v5.0</measure>
    <time_frame>All subjects will be followed up for 60 months from the first dose of Vodobatinib (K0706)</time_frame>
    <description>PART C</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">303</enrollment>
  <condition>Healthy (For Part A)</condition>
  <condition>Chronic Myeloid Leukemia (for Part B and C)</condition>
  <arm_group>
    <arm_group_label>Vodobatinib (K0706) capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vodobatinib (K0706) capsules</intervention_name>
    <description>Part A: Vodobatinib (K0706) capsules in single ascending doses.&#xD;
Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.&#xD;
Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily.</description>
    <arm_group_label>Vodobatinib (K0706) capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to give written, and dated, informed consent&#xD;
&#xD;
          -  Male or female aged ≥ 18 years&#xD;
&#xD;
          -  Willing and able to comply with the scheduled visits&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  Subjects diagnosed with Ph+ CML-CP, Ph+ CML-AP, Ph+ CML-BP, who are resistant and/or&#xD;
             intolerant to ≥ 3 prior TKIs one of which includes ponatinib (Part C).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of T315I (PART C)&#xD;
&#xD;
          -  Any major surgery, as determined by the Investigator, within 4 weeks of IMP&#xD;
             administration&#xD;
&#xD;
          -  Inability to undergo venipuncture and/or tolerate venous access&#xD;
&#xD;
          -  Positive exclusion tests: urine pregnancy tests (if applicable), HIV, hepatitis B&#xD;
             surface antigen, or hepatitis C virus&#xD;
&#xD;
          -  Known or suspected history of significant drug abuse as judged by the Investigator&#xD;
&#xD;
          -  Received any other investigational agent within 30 days or a washout of at least 5&#xD;
             half-lives, whichever is longer of IMP administration&#xD;
&#xD;
          -  Subjects who are eligible for potentially curative therapy that is available,&#xD;
             including hematopoietic stem cell transplant&#xD;
&#xD;
          -  Another primary malignancy within the past 3 years or earlier (except for adequately&#xD;
             treated non-melanoma skin cancer or cervical cancer in situ&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head, Clinical development</last_name>
    <phone>+9122 66455645</phone>
    <email>clinical.trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation, Innovative Clinical Research Institute</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richy Agajanian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematologic Malignancy Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanxing Chai-Ho</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Yaghmour</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Board of Regents of the University System of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Cortes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamid Sayar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James McCloskey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center - MAIN</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Seiter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darla Liles</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Whiteley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesid Alvarado-Valero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Deininger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Granacher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violaine Havelange</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vandenberghe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <state>Bouches-du-Rhône</state>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude Charbonnier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux cedex</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Etienne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges cedex</city>
        <state>Haute Vienne</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Turlure</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes cedex 9</city>
        <state>Ille Et Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Escoffre-Barbe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes cedex 1</city>
        <state>Loire Atlantique</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Dubruille</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers - Hôpital Hôtel Dieu</name>
      <address>
        <city>Angers</city>
        <state>Maine Et Loire</state>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Hunault</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital de Brabois Adultes</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Meurthe Et Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès Guerci-Bresler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez - CHRU Lille</name>
      <address>
        <city>Lille cedex</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Coiteux</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris cedex 10</city>
        <state>Paris</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Rea</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <state>Rhone</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Nicolini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Thomas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny cedex</city>
        <state>Seine Saint Denis</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Braun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens - Hopital Sud</name>
      <address>
        <city>Salouel</city>
        <state>Somme</state>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gouin Charbonnier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Hôpital la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <state>Vienne</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Cayssials</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Nagy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arpad Illes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Rejto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussain Alizadeh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince Aly Khan Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tapan Saikia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Navin Khattry</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahyadri Specialty Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shashikant J Apte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital &amp; Research Centre</name>
      <address>
        <city>Madurai</city>
        <state>Tamilnadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna Rathnam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chittaranjan National Cancer Institute</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalyan Mukherjee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tata Medical Centre</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700156</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S Radhakrishnan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forli - Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Lucchesi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Gambacorti Passerini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Policlinico - Vittorio Emanuele&quot; (Presidio Ferrarotto Alessi)</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Stagno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Scappini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Iurlo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ester Pungolino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Eugenio</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Abruzzese</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggi-do</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong-Wook Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viola-Maria Popov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Coltea</name>
      <address>
        <city>Bucuresti</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Borsaru</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic &quot;Prof. Dr. Ion Chiricuta&quot; Cluj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400124</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delia Dima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal Filantropia Craiova</name>
      <address>
        <city>Craiova</city>
        <zip>200143</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luminita Ocroteala</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Targu Mures</name>
      <address>
        <city>Târgu Mureș</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioan Macarie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thuan Heng Charles Chuah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Badalona - Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Xicoy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Ortí</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Universitari de Girona Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Angona Figueras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentín García Gutiérrez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Ayala Diaz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel de Paz Arias</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regina Garcia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fermin Sanchez-Guijo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Antonio Vera Goñi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Montero Cuadrado,</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE5 9NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>de Lavallade Hugues</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W120HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Apperley</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czechia</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>K0706</keyword>
  <keyword>Vodobatinib</keyword>
  <keyword>ponatinib-refractory/intolerant</keyword>
  <keyword>treatment refractory chronic myeloid leukemia</keyword>
  <keyword>Ponatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

